



[Sign Out](#)

Privacy and Data Protection Help Pages



Submission Details	
Status	Accepted
Open Date	01/10/2016
Deadline Date	31/10/2016
Date Submitted	20/10/2016
Type	Performance In Delivering
NHS provider	Northampton General Hospital NHS Trust

Showing records 1 to 9 of 9.

Pages: 1

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?
----	--	---	---------------	-----------------------------------

13440	15/WM/0050	172460	Efficacy and safety of ingenol mebutate gel 0.015% compared to diclofenacsodium gel 3% in subjects with actinic keratosis on the face or scalp	Number Agreed
13441	15/SC/0443	173722	OPTIMISE ? Long term clear skin maintenance treatment optimisation in patients with moderate to severe chronic plaque psoriasis: A randomised, multi-centre, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, saf	Number Agreed
13442	15/NI/0169	184948	The impact of severe hypoglycaemic events requiring interventions in patients with type I diabetes patients treated insulin therapy	Number Agreed

13443	14/WM/0027	144610	<p><b>THEMIS - A multi national randomised double blind placebo-controlled trial to evaluate the effect of Ticagrelor 90mg daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes.</b></p>	Number Agreed
13444	13/EE/0339	122902	<p><b>CCRN 2162 (Cardiovascular outcomes anti-coagulation strategies)</b></p>	Number Agreed

13445	12/SC/0139	98125	A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAS	Number Agreed
14787	12/WS/0300	114081	CCRN 1044 (Acute Coronary Syndrome) - ODYSSEY (EFC 11570)	Number Agreed
14788	13/SC/0054	121560	CCRN 1070 (Stroke AF)	Number Agreed

14791	15/NW/0626	184626	DIAB 4826 - A Phase 3, Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes	Number Agreed
-------	------------	--------	--	---------------

Showing records 1 to 9 of 9.

Pages: 1

< Back



<b>Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)</b>	<b>Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)</b>	<b>Target Date To Recruit Patients Agreed?</b>	<b>Date Agreed to recruit target number of patients</b>	<b>Total Number Of Patients Recruited At The Agreed Target Date</b>	<b>Date That The Trial Closed To Recruitment</b>	<b>Total Number Of Study Participants Recruited</b>
--	--	--	---	---	--	---

8	8	Date Agreed	30/11/2015	8	29/01/2016	8
1	1	Date Agreed	31/03/2016	2	29/01/2016	2
5	5	Date Agreed	29/01/2016	8	17/02/2016	12

<b>20</b>	<b>20</b>	<b>Date Agreed</b>	<b>14/09/2015</b>	<b>6</b>	<b>10/05/2016</b>	<b>10</b>
<b>30</b>	<b>30</b>	<b>Date Agreed</b>	<b>30/09/2015</b>	<b>45</b>	<b>09/05/2016</b>	<b>53</b>



<b>3</b>	<b>3</b>	<b>Not Available / Not Agreed</b>		<b>3</b>	<b>25/02/2016</b>	<b>3</b>
<b>5</b>	<b>5</b>	<b>Date Agreed</b>	<b>31/08/2016</b>	<b>4</b>	<b>02/11/2015</b>	<b>4</b>
<b>20</b>	<b>20</b>	<b>Date Agreed</b>	<b>31/12/2017</b>	<b>9</b>	<b>24/08/2016</b>	<b>9</b>

6	6	Date Agreed	31/03/2017	11	19/08/2016	11
---	---	-------------	------------	----	------------	----

---

<b>Reason For Closure Of Trial</b>	<b>Comments</b>	
--	-----------------	--

<b>Recruitment Finished</b>		
<b>Recruitment Finished</b>	<b>Fast setup recognised by sponsor</b>	
<b>Recruitment Finished</b>	<b>Over recruited</b>	

<b>Recruitment Finished</b>	<b>Care pathway changed mid study hence did not achieve recruitment target</b>	
<b>Recruitment Finished</b>	<b>Over recruited</b>	

<b>Recruitment Finished</b>		
<b>Recruitment Finished</b>		
<b>Recruitment Finished</b>	<b>Recruitment closed early</b>	

<b>Recruitment Finished</b>	<b>Over recruited - top recruiter in the UK</b>	